Leukaemia Trial, Recruiting (NCT00923507)

Leukaemia Trial, Recruiting NCT00923507 Sponsor: National Heart, Lung, and Blood Institute (NHLBI) Condition: Leukaemia

Printed from Voxsanity (voxsanity.com.au) — NCT00923507 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Leukaemia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with a type of blood cancer called CLL (Chronic Lymphocytic Leukemia) or SLL (Small Lymphocytic Lymphoma), either currently receiving treatment, previously treated, or approaching the point where first treatment is about to begin
People who have been diagnosed with LPL (Lymphoplasmacytic Lymphoma) or WM (Waldenström's Macroglobulinemia), which are related blood cancers diagnosed through specific bone marrow and immune cell testing
People aged 18 years or older
People who are generally able to carry out daily activities with little to no limitation due to their illness (this is measured on a medical scale called ECOG, rated 0 to 2 — confirm with trial site what this means for a specific situation)
People who are able to understand what the trial involves and agree to take part by signing a consent form

Who may not be able to join:

The trial lists no exclusion criteria at this time

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 12 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Adrian U Wiestner, M.D., National Heart, Lung, and Blood Institute (NHLBI)

Phone: (301) 402-0797

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT00923507

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Phase: Not Applicable

Status: Recruiting

Condition: Leukaemia

Trial contact: (301) 402-0797

More information: https://clinicaltrials.gov/study/NCT00923507

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with a type of blood cancer called CLL (Chronic Lymphocytic Leukemia) or SLL (Small Lymphocytic Lymphoma), either currently receiving treatment, previously treated, or approaching the point where first treatment is about to begin
People who have been diagnosed with LPL (Lymphoplasmacytic Lymphoma) or WM (Waldenström's Macroglobulinemia), which are related blood cancers diagnosed through specific bone marrow and immune cell testing
People aged 18 years or older
People who are generally able to carry out daily activities with little to no limitation due to their illness (this is measured on a medical scale called ECOG, rated 0 to 2 — confirm with trial site what this means for a specific situation)
People who are able to understand what the trial involves and agree to take part by signing a consent form

Who may not be able to join:

The trial lists no exclusion criteria at this time

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 12 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Registry

ClinicalTrials.gov

Start date

29 May 2008

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Study the natural history of MBL/CLL/SLL in patients prior to the time when their disease requires treatment.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov